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Abstract 
Background Hypoglycaemia is the most frequent complication of treatment with insulin or insulin 
secretagogues in people with diabetes. Severe hypoglycaemia, i.e. event requiring external help 
because of cognitive dysfunction, is associated with a higher risk of adverse cardiovascular outcomes 
and all-cause mortality, but underlying mechanism(s) are poorly understood. There is also a gap in the 
understanding of the clinical, psychological and health economic impact of ‘non-severe’ 
hypoglycaemia and the glucose level below which hypoglycaemia causes harm.  
 
Aim To increase understanding of hypoglycaemia by addressing the above issues over a 4-year 
period.  
 
Methods Hypo-RESOLVE is structured across eight work packages, each with a distinct focus. We 
will construct a large, sustainable database including hypoglycaemia data from >100 clinical trials to 
examine predictors of hypoglycaemia and establish glucose threshold(s) below which hypoglycaemia 
constitutes a risk for adverse biomedical and psychological outcomes, and increases healthcare costs. 
We will also investigate the mechanism(s) underlying the antecedents and consequences of 
hypoglycaemia, the significance of glucose sensor-detected hypoglycaemia, the impact of 
hypoglycaemia in families, and the costs of hypoglycaemia for healthcare systems.  
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Results The outcomes of Hypo-RESOLVE will inform evidence-based definitions regarding the 
classification of hypoglycaemia in diabetes for use in daily clinical practice, future clinical trials and 
as a benchmark for comparing glucose-lowering interventions and strategies across trials. 
Stakeholders will be engaged to achieve broadly adopted agreement. 
 
Conclusion Hypo-RESOLVE will advance our understanding and refine the classification of 
hypoglycaemia, with the ultimate aim being to alleviate the burden and consequences of 
hypoglycaemia in people with diabetes.  
 
 
Background 
Diabetes is a major non-communicable threat to global health, affecting 10% of adults worldwide [1], 
and is among the most expensive chronic health conditions, imposing an increasing burden on 
healthcare resources [2]. Despite different underlying causes and approaches to treatment, both type 1 
and type 2 diabetes can have devastating effects on physical and mental health and can continue to 
reduce both quality of life and life expectancy. Maintaining glucose at or close to recommended target 
levels has been shown to decrease risks of microvascular and macrovascular complications [3–7], and 
improves overall survival in people with recent-onset type 2 diabetes [6].  
Insulin and insulin secretagogues (e.g. sulfonylureas) are effective in managing hyperglycaemia, but 
increase hypoglycaemia risk because their action is independent of glycaemic levels. Hypoglycaemia 
causes profound physiological and cellular stress, with marked stimulation of the autonomic nervous 
system and the hypothalamic–pituitary–adrenal axis, leading to symptoms ranging from feelings of 
unpleasantness to cognitive impairment, serious harm or death. In type 1 diabetes, 4–8% of premature 
deaths have been attributed to hypoglycaemia [8,9], not including the so-called ‘dead-in-bed’ 
syndrome, a mode of sudden death thought to result from hypoglycaemia-induced fatal arrhythmia 
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[10].  Severe hypoglycaemia, defined as an event causing sufficient cognitive dysfunction to require 
assistance from another person for recovery [11], is predictive of two- to threefold higher risks of 
cardiovascular morbidity and mortality in people with type 2 diabetes [12]. A recent analysis 
calculated that an unrealistically high prevalence of comorbid diseases would be needed to explain the 
association by frailty alone [13], yet the mechanisms underlying a causative relationship remain 
undiscovered. 
On average, hypoglycaemia occurs at a rate of two events per week in those with type 1 and two per 
month in those with insulin-treated type 2 diabetes [14]. Reported rates of severe hypoglycaemia vary 
between 0.3 and 3 events per year in unselected cohorts of people with type 1 diabetes [15]. The 
distribution is highly skewed to those with impaired awareness of hypoglycaemia [16,17], a condition 
already recognized early following the discovery of insulin [18] and characterized by reduced ability 
to detect the onset of hypoglycaemia.  Most estimates ignore ‘silent’ events that occur in these 
individuals or during sleep. Significant advances in diabetes management (e.g. insulin analogues, 
subcutaneous pumps, glucose sensor technology and structured education) appear to have had only a 
relatively modest impact on the incidence of hypoglycaemia [19].  
The myriad of definitions for hypoglycaemia contribute to the variation in reported incidence rates of 
hypoglycaemia. The glucose cut-offs below which counter-regulatory responses to, and symptoms of, 
hypoglycaemia appear are not fixed and depend on both non-modifiable factors (e.g. age and 
duration) and modifiable factors (e.g. prior exposure to hyper- and hypoglycaemia) [20,21]. Despite 
agreement about the clinical relevance of any event of low plasma glucose that carries the potential to 
cause harm [22], uncertainty remains about where such harm starts and in whom, making it difficult 
to assign a single glucose threshold value to define hypoglycaemia. The International Hypoglycaemia 
Study Group (IHSG) has proposed a three-level classification: level 1: glucose ≤3.9 mmol/l (70 
mg/dl), representing an alert value; level 2: glucose <3.0 mmol/l (54 mg/dl) to indicate ‘clinically 
important hypoglycaemia’, based on its association with cognitive dysfunction, reductions in 
hypoglycaemic awareness and mortality; and level 3: severe hypoglycaemia, as defined above [11]. 
This classification has been adopted by the American Diabetes Association, the European Association 
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for the Study of Diabetes, the International Society for Paediatric and Adolescent Diabetes [23] and 
the European Medicines Agency (EMA), and by an international expert panel on continuous glucose 
monitoring [24].  
The evidence base supporting this classification remains relatively limited [25], particularly with 
respect to interstitial glucose measurements, which is relevant given the increasing use of glucose 
sensors, both clinically and in trials. Also, data on the health-economic consequences and on patient-
reported outcomes related to ‘non-severe’ hypoglycaemia are largely lacking, but highly relevant in 
clinical practice, as hypoglycaemia affects virtually everyone using insulin. Thus, there is an urgent 
need to increase understanding of hypoglycaemia in diabetes and to provide more robust and 
comprehensive evidence to strengthen and/or refine the IHSG-proposed classification.   
 
Project aim  
The Hypoglycaemia Redefining Solutions for Better Lives (Hypo-RESOLVE) project’s overall aim is 
to reduce the burden and consequences of hypoglycaemia in people with diabetes by increasing our 
understanding of hypoglycaemia, using a comprehensive multilevel approach that addresses 
unanswered questions and unmet needs [26]. In the present paper, we explain how clinicians and 
scientists with expertise in basic, clinical, psychological/behavioural and health-economic aspects of 
hypoglycaemia will work collaboratively with data science and biostatistics experts, industry partners, 
people with diabetes, healthcare organizations and other stakeholders to achieve this aim.  
 
Project outline 
The work of Hypo-RESOLVE is structured across eight work packages (WPs), each of which has a 
distinct (scientific) focus, with strong interconnected linkages (Fig. 1). Central to the project is the 
further elucidation of the link between hypoglycaemia, whether measured by finger pricks or 
continuous glucose monitoring, and clinical (i.e. cardiovascular and mortality) consequences, its 
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underlying mechanism(s), and patient-reported and health-economic outcomes. We will also map 
definitions of hypoglycaemia as they are currently being used in national and international guidelines 
and maintain a close dialogue with regulators, including the EMA, and other stakeholders. 
 
Hypo-RESOLVE database: WP3 and WP4 
It is standard practice for hypoglycaemic events to be secondary or safety outcomes in clinical trials 
involving insulin treatment. A key objective of Hypo-RESOLVE is to collect these events alongside a 
range of clinical outcomes from over 100 clinical trials on insulin treatment and/or glucose 
monitoring in people with type 1 or type 2 diabetes, to construct a large, sustainable database, offering 
the statistical power needed to establish the glucose threshold(s) below which hypoglycaemia 
constitutes a risk. Entry criteria for these trials are: randomized trials initiated in 2001 or later; 
participants with type 1 or type 2 diabetes; insulin treatment alone or in combination with other drugs; 
and trial duration of at least 12 weeks. After a process of de-identification to ensure participant 
anonymity, original data from each trial will be extracted, reformatted and harmonized to the standard 
Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) 
format (http://www.cdisc.org/; Fig. 2). De-identified trial data will be uploaded to a secure server 
behind a firewall, inaccessible for downloads or changes, and subsequently harmonized and pooled 
into a single database, reachable for a variety of statistical analysis tools, implemented in the R 
statistical framework. After agreeing on categorization of hypoglycaemia, e.g. defined by presence (or 
absence) of symptoms, help from another person, certain glucose thresholds and duration, the 
associations with (un)known clinical and psychological consequences will be examined. A statistical 
analysis plan is being constructed and tested to perform analyses on the risk factors for, and 
consequences of, hypoglycaemia. Using data from the Scottish Diabetes Research Network Type 1 
Bioresource [27], a Bayesian posterior distribution method was found to be a better fit to model the 
risk factors for the prediction of hypoglycaemia than the standard approach of negative binomial 
regression (manuscript in preparation).  
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Mechanistic studies: WP2 
The focus of basic research will be first on further elucidation of the pathogenesis of impaired 
awareness of hypoglycaemia. Animal studies with state-of-the-art transgenic approaches will also be 
used to discover novel pathways that contribute to the development of impaired awareness of 
hypoglycaemia as well as to identify therapeutic targets that may help to restore hypoglycaemia 
awareness.  
A second crucial element of the project is to reveal the potential mechanism(s) underlying the 
association between (severe) hypoglycaemia and cardiovascular outcomes, which would complement 
analyses of the above-mentioned Hypo-RESOLVE clinical database. Recent research has shown 
hypoglycaemia to be a pro-inflammatory, potentially pro-atherogenic, stimulus [28], with the 
resulting response potentially modifiable by prior exposure to hypoglycaemia or the level of overall 
glucose control. We will characterize in detail the nature and time course of such inflammatory 
responses, including underlying processes, using hyperinsulinaemic hypoglycaemic glucose clamps. 
During and up to 1 week after the clamp, blood will be sampled and immune cells isolated for 
extensive phenotyping. The primary outcome is the effect of experimental hypoglycaemia on 
inflammatory responses; secondary outcomes include underlying molecular, metabolic and functional 
mechanisms, epigenetic profiles and oxidative stress, as well as cardiac function, assessed by 
echocardiography. The experiments will be conducted in people with: type 1 diabetes with intact 
awareness of hypoglycaemia; type 1 diabetes with impaired awareness of hypoglycaemia; type 1 
diabetes with suboptimal glycaemia (HbA1c >64 mmol/mol [8%]); and insulin-treated type 2 diabetes 
(n=16 each). One group of volunteers without diabetes (n=16), matched to those with type 2 diabetes, 
will undergo the same procedure. Another group (n=32), matched to participants with type 1 diabetes, 
will be randomized to prior exposure to either two episodes of hypoglycaemia or normoglycaemia on 
the day before the clamp procedure.  Sample sizes are based on a power calculation to meet the 
primary outcome for each subgroup separately, with comparisons between groups to be conducted in 
subsequent analyses. The broad inclusion criteria of this study, registered at clinicaltrials.gov 
(NCT03976271), will enable us to assess the impact of awareness of hypoglycaemia, HbA1c, prior 
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hypoglycaemia and duration of diabetes. Moreover, complimentary rodent studies will determine 
whether the effects in immune cells are replicated in specific organs (e.g. the heart) and tissues (e.g. 
adipose tissue), and to examine the impact of recurrent hypoglycaemia on end-organ histopathology 
and function.  
 
Using continuous glucose monitoring to understand hypoglycaemia: WP5 
In the management of insulin-treated diabetes, self-monitoring of blood glucose, with its major 
limitations of (relatively) infrequent glucose measurements at (more or less) standard time points, is 
being superseded by (semi-)continuous glucose monitoring techniques. In the near future, these 
techniques will become increasingly important for monitoring glucose levels and patterns, assessing 
glycaemic targets and evaluating the effects of interventions, particularly in type 1 diabetes and in 
countries where individuals or the healthcare system can afford it. As continuous glucose monitoring 
starts to become used as an outcome measure to determine risk of hypoglycaemia, we also recognize 
that device metrics may be unstable over short durations. Glucose sensor data collected and 
harmonized in the constructed database (WP3) will enable analysis of the optimum duration of 
glucose sensor use and the relative contribution of sampling interval to determine an individual’s risk 
of hypoglycaemia. We will use in silico modelling techniques to glucose sensor data to identify 
behavioural factors, including self-monitoring of blood glucose, carbohydrate counting and missed 
insulin administration, that modify the risk of hypoglycaemia.  
Recent data show that, even in those with intact awareness of hypoglycaemia, up to 60% of episodes 
are asymptomatic and undetected by the individual [29]. This causes a clinical dilemma as to whether 
such events need to be treated or ignored, and raises issues about how people deal, psychologically, 
with visibility of the potentially overwhelming amount of (semi-)continuous data. We will therefore 
conduct a multinational observational study aiming to understand the impact of both symptomatic and 
asymptomatic episodes of low glucose sensor readings. Participants will be asked to wear blinded 
glucose sensors for 10 weeks, in addition to their usual means of glucose monitoring. They will also 
use an app to register all self-treated episodes of hypoglycaemia and answer questions in real-time 
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relevant to various domains of life that may be affected by hypoglycaemia. The primary objective is 
to determine the optimal definition of sensor hypoglycaemia in terms of threshold and duration by 
elucidating the optimum value of these variables that provides the best sensitivity and specificity for 
patient-reported hypoglycaemia. Secondary outcomes include the impact of symptomatic as well as 
asymptomatic hypoglycaemia and low interstitial glucose values on clinical, psychosocial and health-
economic variables, such as activity, sleep quality, energy levels, well-being, quality of life and 
productivity. A sample size calculation based on the number of expected episodes of patient-reported 
hypoglycaemia and sensor-detected hypoglycaemia taken from a series of large observational 
datasets, calculated that 180 adults with type 1 and 325 with type 2 diabetes are required to meet our 
primary objective.  Allowing for withdrawals and to be able to evaluate outcomes in those with 
impaired awareness, we aim to recruit 250 participants with type 1 diabetes, 50 of whom have 
impaired awareness, and 350 with type 2 diabetes (n=600 in total).  We will investigate differences in 
the impact of hypoglycaemia between type 1 and type 2 diabetes, and the impact of other aspects such 
as sleep and baseline hypoglycaemia rate on these factors.  
Psychological burden and health-economic impact: WP6 and WP7 
The potential of hypoglycaemia to cause cognitive decline, social embarrassment, loss of 
consciousness, accidents and physical injury is a well-known cause of fear of hypoglycaemia [30] 
among individuals with diabetes, as well as partners, parents and other family members [31,32]. 
Substantial fear of hypoglycaemia often results in a coping strategy of maintaining glucose levels in 
the higher range, thus accepting increased exposure to hyperglycaemia and greater risks of associated 
vascular complications [33]. Indisputably, hypoglycaemia (and the fear of it) remains a major barrier 
to people with diabetes achieving and maintaining the glucose levels necessary to avoid the long-term 
complications associated with chronic hyperglycaemia [34]. 
To achieve better insight into the overall burden of hypoglycaemia for people with diabetes and their 
families, extensive systematic literature reviews will be performed to collate and critique all 
quantitative and qualitative studies investigating the impact of hypoglycaemia on quality of life and 
associated psychological outcomes among adults or children with diabetes and family members. 
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Findings will be summarized and, where possible, subjected to meta-analyses.  Existing patient-
reported outcome instruments relevant to assessing the burden of hypoglycaemia will be identified, 
and their psychometric characteristics will be summarized and critiqued. This knowledge will be used 
to develop new or refine existing patient-reported outcome instruments that can be used in various 
populations for health-economic evaluation purposes. In addition, these instruments will be developed 
into a preference-based measure, such that it can be used to generate quality-adjusted life-years for 
use in cost–utility analyses. As such, Hypo-RESOLVE will be able to precisely map the health-
economic consequences of hypoglycaemia, including the costs of hypoglycaemia for healthcare 
systems in Europe and elsewhere.  
In parallel, a qualitative multi-country online survey will be conducted to explore the unmet 
psychological needs of people with diabetes and their families in relation to the prevention, 
experience and management of hypoglycaemia. We plan to include 800–1000 participants from 
Denmark, Germany, the Netherlands and the UK, stratified into groups of adults with type 1 or type 2 
diabetes, children and adolescents with diabetes, and family members. The findings will subsequently 
be used to design a multinational quantitative online survey to further address knowledge gaps, 
including the impact of (severe and self-treated) hypoglycaemia in adults and adolescents and on 
relationships, unmet care needs and barriers to talking about hypoglycaemia. 
Integration of the results of Hypo-RESOLVE: WP8 
The findings from Hypo-RESOLVE will be collated into a comprehensive summary for high-level 
communication with stakeholders and development of a consensus guideline with uniformly agreed 
definitions and data collection methods for the standardization of clinical investigations with regard to 
hypoglycaemia. A dialogue has thus been established with key European and American regulators, 
HTA body representatives, professional and diabetes organizations and other stakeholders.  
Project organization: WP1 
The Hypo-RESOLVE consortium comprises 23 partner organizations from academic centres across 
Europe, industry and biotech partners owning the vast majority of global insulin producing capacity 
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and the manufacturing of glucose monitoring devices, respectively, organizations representing people 
with diabetes, and a project management office. A multi-layered governance model has been agreed 
to ensure suitable levels of cooperation, scientific exchange and project management, as well as a 
decision-making process, in order to achieve the project’s objectives. An international Patient 
Advisory Committee has been formed that interacts closely with each of the WPs to ensure that the 
voice of people with diabetes resonates in the direction, goals and strategy of the project. Finally, 
multi-disciplinary Strategic Advisory and Ethics Boards have been appointed to provide reflection 
and feedback from scientific and ethical perspectives, respectively. 
 
Expected impact 
Using detailed and varied statistical analyses, Hypo-RESOLVE will provide robust evidence about 
risk factors and clinical, psychological and health-economic consequences of asymptomatic (i.e. 
sensor-detected), non-severe and severe hypoglycaemia in people with diabetes. Integration of these 
data offers the unique opportunity to refine and solidify an evidence-based classification of 
hypoglycaemia, whether measured in (capillary) blood or the interstitium, for its use in clinical 
practice, trials design and research, and for the development of clinical guidelines. The results of 
Hypo-RESOLVE are expected to be of considerable interest to a broad range of stakeholders, 
including people with diabetes, healthcare professionals, the scientific community, health technology 
assessment bodies, regulators, industry and payers (Table 1). The project’s progress will be reported 
through scientific publications, the Hypo-RESOLVE website (hypo-resolve.eu), social media 
(@HypoResolve), and stakeholder meetings, to ensure widespread dissemination to, and engagement 
with, all those potentially interested in the project’s progress and outcomes and to endorse the 
ramifications of its analyses for classifying hypoglycaemia. 
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Hypo-RESOLVE limitations 
Although comprehensive, Hypo-RESOLVE will not provide answers to all questions relating to 
hypoglycaemia in people with diabetes. In particular, the Hypo-RESOLVE database may be (too) 
limited for directly examining harm of sensor-detected hypoglycaemia and investigating 
hypoglycaemia in certain populations. Children, the elderly, pregnant women, ethnic subgroups and 
people at highest risk of (severe) hypoglycaemia, including those with impaired awareness of 
hypoglycaemia, chronic kidney disease or other chronic comorbidities are usually excluded from most 
clinical trials. However, the harm of sensor-detected hypoglycaemia may be derived indirectly from 
the observational clinical study on continuous glucose monitoring. Also, examining the impact of 
hypoglycaemia on children, and in particular their carers, is a specific objective of the ‘psychology’ 
WP, whereas elderly populations will be included in the health-economic work. Finally, people with 
impaired awareness of hypoglycaemia will be recruited to the experimental, psychological and 
clinical studies, and animal studies will include models of this condition.  
 
Conclusion 
Despite almost 100 years of experience with insulin as a treatment for diabetes and major advances in 
its management, hypoglycaemia remains a continuous threat to people with diabetes who require 
treatment with insulin or secretagogues. The clinical, psychological and health-economic 
consequences of hypoglycaemia and, in particular, the glucose threshold identifying increased risk for 
harm, remain to be fully established. Hypo-RESOLVE will apply a comprehensive multi-level, multi-
disciplinary scientific approach to examine the links between hypoglycaemia (at various levels) and 
potentially harmful outcomes and its underlying mechanism(s), where applicable. Thus, Hypo-
RESOLVE will advance our understanding of hypoglycaemia, so as to alleviate its burden and 
improve the lives of all people affected by diabetes. 
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Table 1 Expected impact of Hypo-RESOLVE for stakeholders 
  
Stakeholder  Expected impact 
People with diabetes  Facilitating patient–clinician interaction when discussing glucose-lowering 
interventions that affect risk of hypoglycaemia 
 Assessment of risk of hypoglycaemia at the individual level  
 More support in relationships with partners, family members, co-workers 
and friends 
 Better appreciation of indirect costs of (non-severe) hypoglycaemia, such as 
overall functioning, sleep, well-being, quality of life, productivity and work-
related absenteeism and presenteeism 
 Advancement of personalised glucose management 
Healthcare 
professionals 
 Improved knowledge of clinical and psychological impact of hypoglycaemia 
(at various levels) 
 Better appreciation of trial outcomes 
 More insight into the pathways underlying hypoglycaemia-sensing and 
impaired awareness of hypoglycaemia  
 Equipped healthcare professionals better to discuss treatment choices with 
people with diabetes and their family members 
Payers  Calculation of the overall costs of the hypoglycaemic burden 
 Enabling more accurate cost-effectiveness of interventions aimed at 
improving glucose control 
 Help with directing resources to where they can be used the most efficiently 
Regulatory authorities  Better understanding of the clinical, psychological and health-economic 
impact of hypoglycaemia, and of valid assessment tools 
 Facilitating the conduct and use of meta-analyses to compare both efficacy 
and (hypoglycaemic) safety of glucose-lowering interventions 
 Providing strong evidence base for development of guidelines and its 
adoption by other stakeholders, including payers 
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Scientific community  Further delineation of mechanisms underlying the link between 
hypoglycaemia and cardiovascular risks 
 Setting the standard for glucose levels to be used in experimental 
hypoglycaemia research (e.g. clamps) 
 Invitation to scientists to use the constructed Hypo-RESOLVE database to 
answer new research questions   
Industry  Enabling better comparisons of glucose-lowering interventions and strategies 
across trials and benchmarking industry’s products against those of 
competitors 
 Harmonization of hypoglycaemia measures by SMBG or CGM will inform 
the industry how to best apply CGM in future clinical trials 
 Discovering new targets for intervention will open avenues for the 
development of novel hypoglycaemic risk reducing pharmaceutical agents 
and technological solutions 
 Helping to better define populations most in need of hypoglycaemia risk 
reducing interventions in clinical trials 
CGM, continuous glucose monitoring; SMBG, self-monitoring of blood glucose. 
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FIGURE 1 Organizational structure and interaction of the work in Hypo-RESOLVE: project 
management [work package (WP)1],  animal and human pre-clinical experiments (WP2),  
construction of the sustainable Hypo-RESOLVE database (WP3), analysis of the Hypo-RESOLVE 
database to refine and solidify the classification of hypoglycaemia (WP4), glucose monitoring studies 
(WP5), psychological burden of hypoglycaemia (WP6), health-economic impact of hypoglycaemia 
(WP7) and interaction with stakeholders and engagement with people affected by or living with 
diabetes (WP8).  
 
FIGURE 2 Workflow for the construction of the Hypo-RESOLVE database. API, application 
programming interface; WP, work package. 
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